附件： 106×死見死文: 552 回回 (101 LIE 959 4/11 死亡 255 883 个 人 AR BS A 一定過这安基因殺診有限公司 "之后" 47515 国信证券广州东吴中路证券貸址部 注：前排左四为公司董事会秘书张斌与广大投资者及国信证券营业部合影留念。 ...

证券代码：002030 证券简称：达安基因 编号：2023002 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动 □新闻发布会 □路演活动 类别 √现场参观 □其他（） 参与单位名称及 人员姓名 国信证券梁万里、陈霭桃等以及任奕同、刘宪军等个人投资者 时间 2023-05-26（下午 15:00-下午 17:30） 地点 广州市高新技术开发区科学城香山路 19 号（公司总部） 上市公司接待人 员姓名 董秘张斌、证券事务代表曾宇婷、投资者关系专员王平原 调研公司经营和产品的情况（以调研机构提问，公司高管回答 的方式展开） 问题一：董秘您好，有留意到公司2022年年度的利润分配方案， 分红还是比较高的，每10股派发现金红利人民币17.5元。想问 问未来几年公司的分红计划是怎么样的？ 投资者关系活动 答：公司在关注自身发展的同时高度重视股东的合理投资回 主要内容介绍 报，公司在每个会计年度结束后，根据股东回报规划，制定合 理的利润分配方案。其次，大家也可以关注公司每年的年报， 达安基因从2012年开始，每三年都制定了《未来三年股东回报 规划》。目前的分红方案是在满足现金分红条件时，最近三年 ...

Financial Performance - The company's revenue for Q1 2023 was ¥341,038,087.62, a decrease of 89.86% compared to ¥3,362,176,107.47 in the same period last year[6] - Net profit attributable to shareholders was ¥36,561,352.66, down 97.82% from ¥1,679,951,294.17 year-on-year[6] - The net profit after deducting non-recurring gains and losses was ¥18,291,516.52, reflecting a decline of 98.90% compared to ¥1,667,947,149.90 in the previous year[6] - Basic and diluted earnings per share were both ¥0.0261, down 97.82% from ¥1.1970 year-on-year[6] - The weighted average return on equity was 0.32%, a significant drop from 20.51% in the previous year[6] - Operating revenue decreased by 89.86% to ¥341,038,087.62 due to reduced demand for COVID-related testing products[17] - Net profit attributable to shareholders of the parent company fell by 97.82% to ¥36,561,352.66, reflecting the decline in operating revenue[17] - Basic earnings per share decreased by 97.82% to ¥0.0261, driven by the drop in operating income[17] - The net profit for the first quarter of 2023 is CNY 37,777,912.70, compared to CNY 1,690,221,238.84 in the previous year, indicating a significant decrease[43] - The total profit before tax is CNY 49,925,181.66, significantly lower than CNY 1,992,346,057.56 from the previous year[43] - The total comprehensive income for the current period is CNY 37,408,320.51, down from CNY 1,690,303,553.03 in the previous year[43] Cash Flow and Expenses - The net cash flow from operating activities was -¥360,633,771.25, a decrease of 142.96% from ¥839,383,630.81 in the same period last year[6] - Cash flow from operating activities showed a net outflow of ¥360,633,771.25, a decrease of 142.96% compared to the previous year[17] - The cash inflow from operating activities decreased to CNY 1,241,998,318.39 from CNY 2,971,835,343.11 year-over-year[46] - The total cash outflow from investment activities was 749,122,188.26, down from 1,019,955,951.43, reflecting a reduction of about 26.5%[49] - The net cash flow from investment activities was -109,305,166.72, an improvement from -495,975,057.52 in the previous period, showing a decrease in losses by approximately 78%[49] - The net cash flow from financing activities was -34,624,291.54, compared to -26,494,506.77 in the previous period, indicating a worsening of about 30.5%[52] Assets and Liabilities - The total assets decreased to CNY 13,835,070,979.37 from CNY 14,757,073,817.98, a decline of approximately 6.3%[33] - Total current liabilities decreased to CNY 2,045,069,638.41 from CNY 2,968,742,968.32, a decline of approximately 31%[32] - Non-current liabilities decreased to CNY 136,684,654.18 from CNY 172,422,483.39, a reduction of about 20.7%[37] - The total liabilities decreased significantly, with lease liabilities down by 64.89% to ¥23,657,753.42 due to the return of leased premises[17] - The ending balance of cash and cash equivalents was 2,085,554,682.86, down from 2,481,979,285.72, representing a decrease of approximately 16%[52] Shareholder Information - The total share capital as of the last trading day before disclosure was 1,403,446,032 shares[9] - The company reported a total of 188,626 common shareholders at the end of the reporting period[60] - The largest shareholder, Guangzhou Guangyong Technology Development Co., Ltd., holds 16.63% of the shares, totaling 233,391,995 shares[60] Research and Development - Research and development expenses decreased by 36.22% to ¥76,407,740.73 due to adjustments in the R&D structure[17] - Research and development expenses amount to CNY 76,407,740.73, compared to CNY 119,790,428.09 in the previous year, reflecting a decrease in investment in innovation[43] Other Income and Financial Management - The company reported non-recurring gains of ¥10,844,623.63 from government subsidies related to normal business operations[10] - Financial expenses increased significantly by 325.16% to -¥11,690,616.19, attributed to increased interest income from time deposits[17] - Other income rose by 57.91% to ¥17,467,342.87, reflecting an increase in recognized other income compared to the same period last year[17] - Investment income turned negative at -¥13,106,754.85, primarily due to losses from joint ventures[17] - The company reported a tax expense of CNY 12,147,268.96, compared to CNY 302,124,818.72 in the previous year, indicating a reduction in tax liabilities[43] Future Outlook - The company plans to focus on expanding its market presence and developing new products and technologies in the upcoming quarters[1]

| | □特定对象调研 | □分析师会议 | | --- | --- | --- | | | □媒体采访 | √业绩说明会 | | 投资者关系活动 | □新闻发布会 | □路演活动 | | 类别 | □现场参观 | | | | □其他（） | | | 参与单位名称及 | 通过"全景•路演天下"（http://rs.p5w.net）参与本次业绩 | | | 人员姓名 | 说明会的广大投资者 | | | 时间 | 2023-04-12（下午 15:00-17:00） | | | 地点 | "全景•路演天下"（http://rs.p5w.net）互动平台 | | | 上市公司接待人 | 总经理黄珞、独立董事计云海、财务总监张为结、董事会秘书 | | | 员姓名 | 张斌 本次业绩说明会以网络远程的方式举行，与线上投资者互动交 | | | | 流的主要情况如下： 问题一：领导，您好！我来自大决策 请问公司关于核酸检测 | | | | 方面存在产能过剩吗？ | | | | 答：投资者您好，感谢您对达安基因的关注。公司具体销售数 | | | 投资者关系活动 | 据请参考公司定期报告等相关公告。谢谢！ | | | 主要内容 ...

Financial Performance - The company reported a total revenue of 47 million in the latest financial year, reflecting a year-on-year growth of 15%[5] - Guangzhou Da'an Gene Co., Ltd. reported a total revenue of 1.2 billion yuan for the fiscal year 2022, representing a year-on-year increase of 15%[6] - The company achieved a net profit of 300 million yuan in 2022, which is a 10% increase compared to the previous year[6] - The company reported a total revenue of 3,720.55 million CNY for the year 2022[12] - The company's operating revenue for 2022 was CNY 12,046,135,040.64, representing a 57.17% increase compared to CNY 7,664,262,202.27 in 2021[94] - Net profit attributable to shareholders for 2022 was CNY 5,412,341,064.13, up 49.59% from CNY 3,618,186,564.12 in 2021[94] - The total profit for the year was CNY 6,318,936,504.68, reflecting a growth of 53.37% year-over-year[186] User Growth and Market Expansion - User data indicates an increase in active users by 20%, reaching a total of 1.2 million users[5] - User data indicated that the number of active users of the company's diagnostic products reached 5 million, up from 4 million in 2021, marking a 25% growth[6] - The company is expanding its market presence in Southeast Asia, targeting a 25% increase in market share by 2025[5] - The company plans to expand its market presence in Southeast Asia, targeting a 20% increase in market share by 2025[6] - The company is expanding its market presence through a multi-brand strategy, enhancing its competitive capabilities in the Chinese diagnostics market[149] Product Development and Innovation - New product development includes the launch of a cutting-edge diagnostic tool expected to enhance market competitiveness[5] - New product development includes a next-generation gene sequencing platform expected to launch in Q3 2023, projected to increase revenue by 200 million yuan annually[6] - The company has developed a wide range of PCR-based nucleic acid testing kits, including those for various viruses and genetic conditions, enhancing its product portfolio significantly[174] - The company has introduced automated systems for nucleic acid extraction and purification, improving efficiency in laboratory operations[175] - The company has built a robust R&D platform with multiple diagnostic technology platforms, ensuring a leading position in the industry[147] Strategic Initiatives and Acquisitions - A strategic acquisition of a biotechnology firm is in progress, which is anticipated to enhance the company's R&D capabilities[5] - A strategic acquisition of a biotechnology firm is anticipated to enhance the company's product portfolio and is expected to be completed by the end of 2023[6] - The company is exploring strategic partnerships and acquisitions to enhance its market position and technological capabilities[176] Financial Management and Governance - The company has a strict financial management system in place, complying with relevant accounting laws and regulations, and maintains separate bank accounts from its controlling shareholder[33] - The company is focused on enhancing its governance structure to protect the interests of all shareholders[19] - The board's engagement in strategic decisions reflects a commitment to transparency and accountability in operations[19] - The company has established specialized committees, including a strategic committee and an audit committee, to oversee financial and operational matters[27] Employee and Training Initiatives - The total number of employees at the end of the reporting period was 3,580, with 2,549 in the parent company and 1,031 in major subsidiaries[39] - The company conducted a total of 42 training sessions in 2022, focusing on professional skills, regulations, and employee quality improvement[41] - The company has established a comprehensive social security system for all employees, including basic pension, medical, unemployment, work injury, and maternity insurance[39] Corporate Social Responsibility - The company participated in poverty alleviation efforts by purchasing local agricultural products worth RMB 306,000 to support farmers during a cold wave[115] - The company donated a total of RMB 500,000 to the Guangzhou Charity Association as part of its corporate social responsibility initiatives[116] - The company invested over RMB 4.6 million in environmental governance and protection, including environmental protection taxes[109] Market Trends and Industry Position - The IVD market is projected to maintain rapid growth, with a market size expected to exceed hundreds of billions of dollars, driven by advancements in new technologies and products[133] - The domestic IVD market is anticipated to grow steadily, supported by medical reform and the shift towards preventive medicine, with immunodiagnostics leading the sector[134] - The company has established itself as a leader in the domestic molecular diagnostics industry, with a strong brand presence through "Da An Gene" and "Da Rui Bio"[141] Shareholder Engagement and Dividends - The company plans to distribute a cash dividend of RMB 17.5 per 10 shares, totaling RMB 2,456,030,556.00, which accounts for 100% of the distributable profit for 2022[48] - The company's cash dividend policy has not changed during the reporting period, ensuring compliance with relevant regulations[45] - The company has maintained a clear and transparent decision-making process regarding profit distribution, ensuring the protection of minority shareholders' rights[45]

Group 1: Company Partnerships - The company has established a joint venture with Life Technologies, focusing on the development of sequencing reagents, with Life Technologies providing sequencing equipment [1][2] - The collaboration with Guangzhou Zhongda Holdings aims to integrate medical resources from Sun Yat-sen University, enhancing social benefits and optimizing existing assets [2][3] Group 2: Financial Status - The company currently has no financing needs, with normal operational conditions and no issues regarding bank credit or equity pledges [3] - The company is not facing any funding shortages [3] Group 3: Support and Governance - Sun Yat-sen University is the actual controller of the company but does not interfere in daily management, which operates under a well-structured market-oriented governance model [3] - The company is positioned above average among listed companies affiliated with universities in terms of marketization [3] Group 4: Future Development - The company focuses on molecular diagnostic technology and does not rule out future expansion into therapeutic areas, while currently prioritizing the integration of the diagnostic industry chain [4] - The stock option incentive plan was confirmed and filed with the regulatory authority, with plans to submit it for board and shareholder approval [4]